NADH不但不延寿，还减寿！NADH过量的三大危害，你知道吗？

时光派抗衰研究院撰稿

NAD+家族的NMN和NR借着股市的威势乘风破浪，它的“一奶同胞”兄弟NADH也在蠢蠢欲动，打着“1片顶4片NMN的第三代NAD+”、“还原型NAD+抗氧化”、“直接转化NAD+强力延寿”的旗号疯狂碰瓷，妄图在富人续命市场分上一杯羹……

正文：

NAD+与NADH：有联系，但区别更大

烟酰胺腺嘌呤二核苷酸（NAD+）是生物体内许多脱氢酶（/氧化酶）的辅酶，有传递氢和电子的功能，在接收别的物质被氧化后脱下来的氢和电子之后，NAD+就变为了还原型烟酰胺腺嘌呤二核苷酸（NADH）[1]。

图注：NAD+的加氢和NADH的脱氢反应相互转化

NAD+和NADH在细胞内各种基础生化反应中相互转化。但一般来说，细胞质内的NAD+/NADH比值约为60-700，线粒体内的NAD+/NADH比值保持在7-8[2,3]。这种NAD+明显多于NADH的数量关系才能维持正常的线粒体膜电位，保证正常的线粒体功能和细胞能量代谢[4-6]。

图注：NAD+/NADH参与糖代谢和生物氧化（@TRENDS in Endocrinology & Metabolism, 时光派编译）

NAD+/NADH的生物学作用，就同“绿巨人浩克”与变身前“班纳”一样，之间有联系，可区别也很大：至少，NAD+通过激活长寿蛋白Sirtuins来延缓衰老的功能，NADH就是没有的。

图注：NAD+与NADH的生物学作用（WEIHAI YANG, et al.）

其中还值得拿出来一讲的是NADH会引发“还原性应激”，很多人看到NADH名字里的“还原型”三个字，会想当然地把它认定为还原剂。但是研究已经证明了，过量的NADH会加速ROS生成，加重氧化[10,11]，“还原型”反倒成了NADH的原罪。

图注：NAD+/NADH与氧化还原和衰老过程的关系（WEIHAI YANG, et al.）

NADH还可能让你的“长寿药”白吃

目前针对NAD+的研究已经证实了：随着年龄增长，某些组织内NAD+不断减少；很多人不知道的是，NADH在这个过程中也在不断增加，与老化相关[18]。

图注：人类脑细胞中总NAD、NAD+和NADH水平随年龄变化[18]

NAD+和NADH之间还有着一种“此消彼长”的关系：一项研究让受试者补充NADH，在用药8周后测定血液单核细胞内NAD+和NADH含量，结果发现细胞内NAD+水平下降，NADH水平上升，NAD+/NADH比值下降[19]。

图注：补充NADH 8周后血单核细胞内NAD+、NADH水平和NAD+/NADH变化[19]

热量限制（CR）是目前公认最有效的“续命”方式，它就是通过调节Sir2降低NADH水平、升高NAD+/NADH比值来起到延寿的作用[20]。

图注：NAD+/NADH ——“天平的两端”

综上所述，我们认为：以目前的研究来看，外源性补充NADH会提升细胞内NADH水平，降低NAD+水平，可能不利于延长寿命。如果和NMN、NR这类NAD+补充剂“长寿药”同服，最终的结果是花了双份钱却 “吃了个寂寞”。

把NADH包装成“长寿药”的商人，其实更应该多吃吃自家产品——“救智、补脑”。

NADH真正的跑道：可能是神经 “万灵药”，却并非“聪明药”

NADH真正“跑起来”，是学者们发现了NADH能间接地为酪氨酸羟化酶催化的多巴胺合成限速步骤提供还原当量，促进内源性左旋多巴（多巴胺前体物质）的合成[21]；同时也有证据表明，NADH能够增加血浆左旋多巴的生物利用度[22]。NADH还有着调节线粒体能量代谢、调节钙稳态、调节大脑基因表达、抗凋亡等多种作用，让它成为有望成为攀越神经系统疾病治疗这座高峰的“种子选手”。

上世纪90年代以来，用NADH治疗各种神经系统疾病有效的研究报道一时间如雨后春笋般出现——改善帕金森病（PD）[23,24]、阿尔茨海默症（AD,“老年痴呆”） [22]、 “时差病”[25]和慢性疲劳综合征（CFS）[26,27]；甚至有望将其用于治疗亨廷顿舞蹈病（HD）、脑外伤后/脑梗死后脑损伤、多发性硬化症（MS）和脑瘤等“绝症” [28-36]。

多巴胺与学习和记忆有着千丝万缕的联系[37,38]，成就了今天NADH在保健品领域“考生必备‘聪明药’”的地位，很多人试图服用它来集中注意力、提升工作学习效率。

图注：某宝上的NADH“聪明药”广告

但是，目前的研究只证实了服用NADH可能改善病理状态下（AD、CFS和时差调整状态）患者的认知功能，在正常人身上的有效性和安全性的研究尚缺。因此，我们也不主张正常人“拿到半截就开跑”，将NADH作为提高记忆和学习能力的补剂来服用。

时光派点评

对人体自身奥秘的探索过程，和那些试图解秘森罗万象的所有科学研究过程都一样——就像拼图游戏，是用碎片去构拟还原出一个全景，这个过程中难免会拼错那么一块两块，需要不断地去修正；我们现在所能看到的是现有拼图的模样，可能只是成品的冰山一角。

所以，我们只能告诉你，在结合现有研究证据分析之后，我们认为：NADH有潜力成为一款治疗许多神经系统疾病的好药，但未必利于延寿，不建议未患影响认知功能的疾病的正常人把NADH当作补剂去服用。希望NADH早日“青春归位”，不会再被用来骗人，回到属于自己的领域去发光发热！

每次与NAD+代谢流上的相关物质接触，笔者总能闻到一股难以名状的“怪味儿”：NAD+利益相关者把NADH贬得一钱不值，NADH把NAD+妖化成洪水猛兽，NAD+各类补充剂明争暗斗……

再

我想，负责任的科普应该是罗列事实而臧否两论。我们不反对靠科普来变现，所以我们也开起了自己的小店；但是以捞钱为目的而扭曲事实去科普，说实话，真的有点臭。

参考文献：

[1] Mitchell P: Keilin’s respiratory chain concept and its chemiosmotic consequences. Science 1979; 206:1148.

[2] Veech, R.L. et al. (1972) The time-course of the effects of ethanol on the redox and phosphorylation states of rat liver. Biochem. J. 127, 387–397.

[3] Williamson, D.H. et al. (1967) The redox state of free nicotinamide- adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem. J. 103, 514–527.

[4] Ying,W.(2008)NAD+/NADH and NADP+/NADPH incellular functions and cell death: regulation and biological consequences. Antioxid. Redox Signal. 10, 179–206.

[5] Cheng, Z. et al. (2010) Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 21, 589–598.

[6] Houtkooper,R.H.etal.(2010)The secret life of NAD+:an old metabolite controlling new metabolic signaling pathways. Endocr. Rev. 31, 194–223.

[7] Kirsch M and De Groot H. NAD(P)H, a directly operating antioxidant? F ASEB J 15: 1569–1574, 2001.

[8] McGuinness ET and Butler JR. NAD+ kinase—-a review. Int J Biochem 17: 1–11, 1985.

[9] Olek RA, Ziolkowski W, Kaczor JJ, Greci L, Popinigis J, and Antosiewicz J. Antioxidant activity of NADH and its analogue—an in vitro study. J Biochem Mol Biol 37: 416–421, 2004.

[10] Jaeschke H, Kleinwaechter C, and Wendel A. NADH-dependent reductive stress and ferritin-bound iron in allyl alcohol-induced lipid peroxidation in vivo: the protective effect of vitamin E. Chem Biol Interact 81: 57–68, 1992.

[11] Zhang Z, Blake DR, Stevens CR, Kanczler JM, Winyard PG, Symons MC, Benboubetra M, and Harrison R. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res 28: 151–164, 1998.

[12] Kaplin AI, Snyder SH, and Linden DJ. Reduced nicotinamide adenine dinucleotide-selective stimulation of inositol 1,4,5-trisphosphate receptors mediates hypoxic mobilization of calcium. J Neurosci 16: 2002–2011, 1996.

[13] Zima AV, Copello JA, and Blatter LA. Differential modulation of cardiac and skeletal muscle ryanodine receptors by NADH. FEBS Lett 547: 32–36, 2003.

[14] Zhang Q, Piston DW, and Goodman RH. Regulation of corepressor function by nuclear NADH. Science 295: 1895–1897, 2002.

[15] Rutter J, Reick M, Wu LC, and McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293: 510–514, 2001.

[16] Nadlinger K, Birkmayer J, Gebauer F, and Kunze R. Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes. Neuroim-munomodulation 9: 203–208, 2001.

[17] Zhu K, Swanson RA, and Ying W. NADH can enter into astrocytes and block poly (ADP-ribose) polymerase-1-mediated astrocyte death. Neuroreport 16: 1209–1212, 2005.

[18] Zhu, X.-H., Lu, M., Lee, B.-Y., Ugurbil, K., & Chen, W. (2015). In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proceedings of the National Academy of Sciences, 112(9), 2876–2881.

[19] Castro-Marrero, J., Cordero, M. D., Segundo, M. J., Sáez-Francàs, N., Calvo, N., Román-Malo, L., … Alegre, J. (2015). Does Oral Coenzyme Q10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in Chronic Fatigue Syndrome? Antioxidants & Redox Signaling, 22(8), 679–685.

[20] Lin, S. J., E. Ford, M. Haigis, G. Liszt & L. Guarente: Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev, 18, 12-6(2004).

[21] Swerdlow, R. H.: Is NADH effective in the treatment of Parkinson's disease? Drugs Aging, 13, 263-8(1998).

[22] Demarin V, Podobnik SS, Storga Tomic D, and Kay G. Treatment of Alzheimer’s disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs Exp Clin Res 30: 27–33, 2004.

[23] Kuhn W, Muller T, Winkel R, Danielczik S, Gerstner A, Hacker R, Mattern C, and Przuntek H. Parenteral application of NADH in Parkinson’s disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm 103: 1187–1193, 1996.

[24] Birkmayer, J. G., C. Vrecko, D. Volc & W. Birkmayer: Nicotinamide adenine dinucleotide (NADH)——a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl, 146, 32-5(1993).

[25] NASA: Stabilized NADH as a Countermeasure for Jet Lag. Report/Patent Number JSC-CN-6528.

[26] Forsyth, L. M., Preuss, H. G., MacDowell, A. L., Chiazze, L., Birkmayer, G. D., & Bellanti, J. A. (1999). Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Annals of Allergy, Asthma & Immunology, 82(2), 185–191.

[27] Alegre, J., Rosés, J. M., Javierre, C., Ruiz-Baqués, A., Segundo, M. J., & Fernández de Sevilla, T. (2010). Nicotinamida adenina dinucleótido (NADH) en pacientes con síndrome de fatiga crónica. Revista Clínica Espaola, 210(6), 284–288.

[28] Vis, J. C., E. Schipper, R. T. de Boer-van Huizen, M. M. Verbeek, R. M. de Waal, P. Wesseling, H. J. ten Donkelaar & B. Kremer: Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol (Berl), 109, 321-8(2005).

[29] Virag, L. & C. Szabo: The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev, 54, 375-429(2002).

[30] Satchell, M. A., X. Zhang, P. M. Kochanek, C. E. Dixon, L. W. Jenkins, J. Melick, C. Szabo & R. S. Clark: A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma. J Neurochem, 85, 697-708(2003).

[31] LaPlaca, M. C., J. Zhang, R. Raghupathi, J. H. Li, F. Smith, F. M. Bareyre, S. H. Snyder, D. I. Graham & T. K. McIntosh: Pharmacologic inhibition of poly (ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats. J Neurotrauma, 18, 369-76(2001).

[32] Kofler, J., T. Otsuka, Z. Zhang, R. Noppens, M. R. Grafe, D. W. Koh, V. L. Dawson, J. M. de Murcia, P. D. Hurn & R. J. Traystman: Differential effect of PARP-2 deletion on brain injury after focal and global cerebral ischemia. J Cereb Blood Flow Metab, 26, 135-41(2006).

[33] Gilgun-Sherki, Y., E. Melamed & D. Offen: The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol, 251, 261-8(2004).

[34] Kauppinen, T. M., S. W. Suh, C. P. Genain & R. A. Swanson: Poly (ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. J Neurosci Res, 81, 190-8(2005).

[35] Tentori, L., I. Portarena, F. Torino, M. Scerrati, P. Navarra & G. Graziani: Poly (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia, 40, 44-54(2002).

[36] Tentori, L., C. Leonetti, M. Scarsella, G. D'Amati, M. Vergati, I. Portarena, W. Xu, V. Kalish, G. Zupi, J. Zhang & G. Graziani: Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res, 9, 5370-9(2003).

[37] Liang, L., Wang, R., & Zhang, Z. (2012). The Effect of Dopamine on Working Memory. Neural Processing Letters, 35(3), 257–263.

[38] Roffman, J. L., Tanner, A. S., Eryilmaz, H., Rodriguez-Thompson, A., Silverstein, N. J., Ho, N. F., … Catana, C. (2016). Dopamine D1 signaling organizes network dynamics underlying working memory. Science Advances, 2(6), e1501672–e1501672.